<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898950</url>
  </required_header>
  <id_info>
    <org_study_id>2004-001418-14</org_study_id>
    <nct_id>NCT00898950</nct_id>
  </id_info>
  <brief_title>Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes</brief_title>
  <official_title>The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Portsmouth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Portsmouth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was set up to assess the effects of different doses of aspirin when compared with
      placebo (dummy drug), used sequentially over a 2 week study period with a 2 week wash-out
      (rest period) in between, in people with type-2 diabetes and high cardiovascular risk.
      Specifically, its effects on different factors which are thought to contribute to diabetes
      such as insulin resistance (body's ability to effectively use insulin), dysglycaemia (excess
      glucose in the blood), oxidative stress (effects from accumulation of by-products of
      metabolism), endothelial function (function of lining of blood vessels) and inflammation were
      studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in markers of oxidative stress, endothelial function, glycaemic control, and insulin resistance</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Aspirin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effects of using aspirin 75 mgs/day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Effects of using aspirin 300 mgs/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin 900mgs QID orally for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 75mgs/day orally for 2 weeks.</description>
    <arm_group_label>Aspirin low dose</arm_group_label>
    <other_name>acetyl salicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>300mgs/day orally for 2 weeks</description>
    <arm_group_label>Aspirin medium dose</arm_group_label>
    <other_name>acetyl salicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>aspirin 900mgs QID orally for 2 weeks</description>
    <arm_group_label>aspirin high dose</arm_group_label>
    <other_name>acetyl salicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo tablet</intervention_name>
    <description>placebo tablet with lactose and excipients.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes type 2

          -  age &gt; 18 and &lt; 70

          -  high cardiovascular risk

        Exclusion Criteria:

          -  presence of active/established cardiovascular disease (ischaemic heart disease,
             cerebrovascular disease or peripheral vascular disease)

          -  insulin treatment

          -  patients with known peptic ulcer disease or those on anti-coagulation

          -  significant renal impairment

          -  aspirin intolerance

          -  use of anticoagulants

          -  significant liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajeev P Raghavan, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Portsmouth Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael H Cummings, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Portsmouth Hospitals NHS TRust &amp; University of Portsmouth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Pharmacy and Biomedical Sciences, University of Posrtmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO1 2DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Centre, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 11, 2009</last_update_submitted>
  <last_update_submitted_qc>May 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr MH Cummings</name_title>
    <organization>Portsmouth Hospitals NHS Trust &amp; University of Portsmouth</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>aspirin</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>endothelial function</keyword>
  <keyword>inflammation</keyword>
  <keyword>photoplethysmography</keyword>
  <keyword>dysglycaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

